Neuronal cell-based high-throughput screen for enhancers of mitochondrial function reveals luteolin as a modulator of mitochondria-endoplasmic reticulum coupling
Luana Naia,
Catarina M. Pinho,
Giacomo Dentoni,
Jianping Liu,
Nuno Santos Leal,
Duarte M. S. Ferreira,
Bernadette Schreiner,
Riccardo Filadi,
Lígia Fão,
Niamh M. C. Connolly,
Pontus Forsell,
Gunnar Nordvall,
Makoto Shimozawa,
Elisa Greotti,
Emy Basso,
Pierre Theurey,
Anna Gioran,
Alvin Joselin,
Marie Arsenian-Henriksson,
Per Nilsson,
A. Cristina Rego,
Jorge L. Ruas,
David Park,
Daniele Bano,
Paola Pizzo,
Jochen H. M. Prehn,
Maria Ankarcrona
Affiliations
Luana Naia
Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet
Catarina M. Pinho
Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet
Giacomo Dentoni
Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet
Jianping Liu
Department of Medicine-Huddinge, Karolinska Institutet
Nuno Santos Leal
Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet
Duarte M. S. Ferreira
Department of Physiology and Pharmacology, Karolinska Institutet
Bernadette Schreiner
Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet
Riccardo Filadi
Department of Biomedical Sciences, University of Padua
Lígia Fão
CNC-Center for Neuroscience and Cell Biology, University of Coimbra
Niamh M. C. Connolly
Royal College of Surgeons in Ireland, Department of Physiology & Medical Physics Department
Pontus Forsell
AlzeCure Pharma AB
Gunnar Nordvall
AlzeCure Pharma AB
Makoto Shimozawa
Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet
Elisa Greotti
Department of Biomedical Sciences, University of Padua
Emy Basso
Department of Biomedical Sciences, University of Padua
Pierre Theurey
Department of Biomedical Sciences, University of Padua
Anna Gioran
German Center for Neurodegenerative Diseases (DZNE)
Alvin Joselin
Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary
Marie Arsenian-Henriksson
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
Per Nilsson
Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet
A. Cristina Rego
CNC-Center for Neuroscience and Cell Biology, University of Coimbra
Jorge L. Ruas
Department of Physiology and Pharmacology, Karolinska Institutet
David Park
Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary
Daniele Bano
German Center for Neurodegenerative Diseases (DZNE)
Paola Pizzo
Department of Biomedical Sciences, University of Padua
Jochen H. M. Prehn
Royal College of Surgeons in Ireland, Department of Physiology & Medical Physics Department
Maria Ankarcrona
Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet
Abstract Background Mitochondrial dysfunction is a common feature of aging, neurodegeneration, and metabolic diseases. Hence, mitotherapeutics may be valuable disease modifiers for a large number of conditions. In this study, we have set up a large-scale screening platform for mitochondrial-based modulators with promising therapeutic potential. Results Using differentiated human neuroblastoma cells, we screened 1200 FDA-approved compounds and identified 61 molecules that significantly increased cellular ATP without any cytotoxic effect. Following dose response curve-dependent selection, we identified the flavonoid luteolin as a primary hit. Further validation in neuronal models indicated that luteolin increased mitochondrial respiration in primary neurons, despite not affecting mitochondrial mass, structure, or mitochondria-derived reactive oxygen species. However, we found that luteolin increased contacts between mitochondria and endoplasmic reticulum (ER), contributing to increased mitochondrial calcium (Ca2+) and Ca2+-dependent pyruvate dehydrogenase activity. This signaling pathway likely contributed to the observed effect of luteolin on enhanced mitochondrial complexes I and II activities. Importantly, we observed that increased mitochondrial functions were dependent on the activity of ER Ca2+-releasing channels inositol 1,4,5-trisphosphate receptors (IP3Rs) both in neurons and in isolated synaptosomes. Additionally, luteolin treatment improved mitochondrial and locomotory activities in primary neurons and Caenorhabditis elegans expressing an expanded polyglutamine tract of the huntingtin protein. Conclusion We provide a new screening platform for drug discovery validated in vitro and ex vivo. In addition, we describe a novel mechanism through which luteolin modulates mitochondrial activity in neuronal models with potential therapeutic validity for treatment of a variety of human diseases.